SAFE Study:
Safety and Efficacy Analysis of FRED™ Embolic Device in Aneurysm Treatment
FRED™ Flow Diverter
"SAFE study analysis at 1 year confirms the excellent safety profile of the FRED™ device for aneurysm treatment, with low morbidity and mortality rates (2.9% and 1.9%, respectively) and demonstrates its efficacy (adequate occlusion in 73/90 (81.1%)."
- Patients
103
- Country
France
- Clinical Centers
13
- Design
Single arm prospective
- Scope
Patients ≥ 18 y.o. with a non acutely ruptured or recanalized IC aneurysm, on the anterior circulation, requiring endovascular treatment, mRS ≤ 2, eligible to be treated with FRED™ /FRED™ Jr in French centers.
- Purpose
Assess Safety and Efficacy of FRED™ / FRED™ Jr devices in Aneurysm Treatment to obtain reimbursement in France.
Endpoints
Efficacy: Aneurysm complete occlusion without ˃ 50% parent artery stenosis at 6 months (assessed by Corelab)
Safety: Morbidity & Mortality rate at 6 months, defined as an mRS > 2
Efficacy results
Treatment success: 95.1%
At 6 months:
Complete occlusion: 61.1%
No parent artery stenosis or <50%: 92.6%
At 12 months:
Complete occlusion: 73.3 %
No parent artery stenosis or <50%: 93.3%
Retreatment rate: 2.2%
Safety results
At 6 months:
Morbidity: 2%
Mortality: 1%
Thromboembolic (TE) complications: 4.9%
At 12 months:
Morbidity: 2.9% (incl. 1 intraoperative TE, 1 Long term TE, 1 delayed aneurysm rupture)
Mortality: 1.9% (incl. 1 dissection during catheterization and 1 cancer)
Thromboembolic complications: 6.8%
Study publications
LINK TO STUDY PAGE ClinicalTrials.gov ID NCT02921698
Please refer to Instruction for Use (IFU) in the specific market/country that you are looking into:
Explore more studies
UK Study: Safety and Efficacy Analysis of FRED™/FRED™Jr Embolic Device in Aneurysm Treatment
FRED™ Flow Diverter
Request more information
The information you provide through this form is necessary to respond to your request and may be shared with the relevant Terumo Neuro group entity or entities responsible for handling it. For more information on how we process your personal data and on your rights, please refer to our privacy policy.